These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23493136)

  • 1. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Schultheis B; Folprecht G; Kuhlmann J; Ehrenberg R; Hacker UT; Köhne CH; Kornacker M; Boix O; Lettieri J; Krauss J; Fischer R; Hamann S; Strumberg D; Mross KB
    Ann Oncol; 2013 Jun; 24(6):1560-7. PubMed ID: 23493136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
    Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
    Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin.
    Rietveld PCS; Sassen SDT; Guchelaar NAD; van Eerden RAG; de Boer NL; van den Heuvel TBM; Burger JWA; Mathijssen RHJ; Koch BCP; Koolen SLW
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1006-1016. PubMed ID: 38634204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
    Strumberg D; Scheulen ME; Schultheis B; Richly H; Frost A; Büchert M; Christensen O; Jeffers M; Heinig R; Boix O; Mross K
    Br J Cancer; 2012 May; 106(11):1722-7. PubMed ID: 22568966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.
    Moy RH; Dos Santos Fernandes G; Jonsson P; Chou JF; Basunia A; Ku GY; Chalasani SB; Boyar MS; Goldberg Z; Desai AM; Gabler A; Berger MF; Tang LH; Hechtman JF; Kelsen DP; Schattner M; Ilson DH; Solit DB; Taylor BS; Schultz N; Capanu M; Janjigian YY
    Oncologist; 2020 Jan; 25(1):e68-e74. PubMed ID: 31570517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.
    Lin CY; Lin TH; Chen CC; Chen MC; Chen CP
    PLoS One; 2018; 13(1):e0190497. PubMed ID: 29304109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.
    Adenis A; Ghiringhelli F; Gauthier L; Mazard T; Evesque L; Evrard A; Chalbos P; Moussion A; Gourgou S; Ychou M
    Cancer Chemother Pharmacol; 2024 Jul; ():. PubMed ID: 38987363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.
    Fujita K; Taguchi D; Fukuda K; Yoshida T; Shimazu K; Shinozaki H; Shibata H; Miura M
    Invest New Drugs; 2024 Jun; 42(3):252-260. PubMed ID: 38517650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management.
    Khan G; Moss RA; Braiteh F; Saltzman M
    Cancer Manag Res; 2014; 6():93-103. PubMed ID: 24623990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study.
    Ramaswamy A; Ostwal V; Pande N; Sharma A; Patil S; Thippeswamy R; Ghadyalpatil N; Roy R; Peshwe H; Poladia B; Rajamanickam D; Rangarajan B; Neelesh Reddy PR; Pandita V; Mukherjee A; Thoke A; Sarkar A; Satish CT; Shashidara H; Banavali SD
    South Asian J Cancer; 2019; 8(1):22-26. PubMed ID: 30766846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol.
    Coriat R; Sibaud V; Bourgeois V; Manfredi S; Artru P; Trouilloud I; Kremliovsky M; Arvis P; Palma MD
    Dig Liver Dis; 2023 Aug; 55(8):1019-1025. PubMed ID: 37217373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):114. PubMed ID: 38262962
    [No Abstract]   [Full Text] [Related]  

  • 14. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
    Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
    Yoshino T; Komatsu Y; Yamada Y; Yamazaki K; Tsuji A; Ura T; Grothey A; Van Cutsem E; Wagner A; Cihon F; Hamada Y; Ohtsu A
    Invest New Drugs; 2015 Jun; 33(3):740-50. PubMed ID: 25213161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.
    Psyrri A; Rampias T; Vermorken JB
    Ann Oncol; 2014 Nov; 25(11):2101-2115. PubMed ID: 25057165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.